3 results
The primary objectives of this study are: - To evaluate the efficacy of GFT505 80mg and GFT505 120mg once daily (according to adaptive design, after 6-month interim safety analysis of the 80mg data on at least 50% of patients) for 52 weeks versus…
Primary: Progression Free Survival (PFS) in patients treated with AUY922 versus pemetrexed or docetaxel.Secondary: Overall response rate, disease control rate, overall survival, safety and tolerability, PK.
To investigate the in vivo performance and safety of a novel medical device for the injection of holmium-166 microspheres during SIRT. This main potential advantage of this device is that it allows for injection of a during treatment determined dose…